Covestor Ltd Invests $58,000 in PerkinElmer, Inc. (NYSE:PKI)

Covestor Ltd bought a new position in shares of PerkinElmer, Inc. (NYSE:PKIGet Rating) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 287 shares of the medical research company’s stock, valued at approximately $58,000.

Several other institutional investors also recently bought and sold shares of PKI. Capital Research Global Investors grew its position in shares of PerkinElmer by 2.3% during the 3rd quarter. Capital Research Global Investors now owns 12,589,746 shares of the medical research company’s stock worth $2,181,699,000 after buying an additional 281,537 shares during the period. Tesco Pension Investment Ltd grew its position in shares of PerkinElmer by 67.5% during the 4th quarter. Tesco Pension Investment Ltd now owns 593,025 shares of the medical research company’s stock worth $119,234,000 after buying an additional 238,889 shares during the period. Robeco Schweiz AG grew its position in shares of PerkinElmer by 24.7% during the 4th quarter. Robeco Schweiz AG now owns 1,030,504 shares of the medical research company’s stock worth $207,193,000 after buying an additional 204,292 shares during the period. Robeco Institutional Asset Management B.V. boosted its position in PerkinElmer by 22.9% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 1,059,901 shares of the medical research company’s stock worth $213,102,000 after acquiring an additional 197,696 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in PerkinElmer by 29.4% during the 4th quarter. JPMorgan Chase & Co. now owns 838,889 shares of the medical research company’s stock worth $168,667,000 after acquiring an additional 190,630 shares during the last quarter. Institutional investors own 89.27% of the company’s stock.

PKI stock opened at $143.55 on Friday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.94 and a quick ratio of 1.43. The stock has a market capitalization of $18.11 billion, a price-to-earnings ratio of 23.49, a PEG ratio of 0.42 and a beta of 1.16. The business’s fifty day moving average price is $161.88 and its two-hundred day moving average price is $174.61. PerkinElmer, Inc. has a fifty-two week low of $137.37 and a fifty-two week high of $203.16.

PerkinElmer (NYSE:PKIGet Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The medical research company reported $2.41 earnings per share for the quarter, topping the consensus estimate of $2.08 by $0.33. The firm had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.19 billion. PerkinElmer had a return on equity of 18.98% and a net margin of 14.54%. The company’s quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter last year, the business earned $3.72 EPS. Research analysts expect that PerkinElmer, Inc. will post 7.34 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 12th. Shareholders of record on Friday, July 22nd will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.20%. The ex-dividend date of this dividend is Thursday, July 21st. PerkinElmer’s payout ratio is 4.58%.

A number of equities analysts have weighed in on the company. Citigroup reduced their price target on PerkinElmer from $185.00 to $170.00 in a research report on Wednesday, May 4th. StockNews.com assumed coverage on PerkinElmer in a research report on Thursday, March 31st. They set a “hold” rating for the company. Robert W. Baird reduced their price target on PerkinElmer from $216.00 to $198.00 in a research report on Wednesday, May 4th. Finally, Barclays assumed coverage on PerkinElmer in a research note on Tuesday. They set an “underweight” rating and a $125.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, PerkinElmer presently has a consensus rating of “Buy” and an average price target of $159.84.

In other news, insider Daniel R. Tereau sold 6,696 shares of the stock in a transaction on Monday, March 14th. The stock was sold at an average price of $165.84, for a total transaction of $1,110,464.64. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.52% of the company’s stock.

PerkinElmer Company Profile (Get Rating)

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.

Featured Articles

Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKIGet Rating).

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.